The authors would like to thank the patient and her family. We also gratefully acknowledge the assistance of Michelle Flores, Melodee Smith, Sherry Littlefield, Laura Connelly-Smith, James Riddle, Wayne Monsky, Ednus Warren, Stan Riddell, Daniel Flynn, Frank Bohmer, Alain Charest, David Baker, Brian Druker, Lance Stewart, Monika Davare, Julie Gralow, Bernie McLaughlin, Jennifer Specht, VK Gadi, Paul Martin, Corinne Fligner, David Yadock, Jennifer Spokely, Krystal Malhotra, Stephanie Parker, Daniel Campton, Josh Nordberg, Nick Drovetto, Zhijun Duan, Nicole Heying, Leila Ritter, and NW BioTrust.
Drs. Ramirez, Stilwell, and Kaldjian are employees of RareCyte; Drs. Madan, Austin, and Howard are employees of Covance/LabCorp Inc.; Drs. Komashko and Mecham are employees of Trialomics LLC; and Drs. Ronen and Dutkowski are employees of Data4Cure Inc. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. This publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000423. Funding for this work was provided by South Sound CARE, the Gary E. Milgard Family Foundation, the Pano Koumantaros Cancer Research Fund, the Washington Research Foundation, the University of Washington School of Medicine, NIDDK grant P30 DK56465 (S.H.), and private donors.
PleasanceEDCheethamRKStephensPJ. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature2010;463:191–196.
ForbesSABindalNBamfordS. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res2010;39:D945–950.
GerlingerMRowanAJHorswellS. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med2012;366:883–892.
ShahSPRothAGoyaR. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature2012;486:395–399.
EirewPSteifAKhattraJ. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature2015;518:422–426.
WagleNGrabinerBCVan AllenE. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med2014;371:1426–1433.
WagleNGrabinerBCVan AllenE. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov2014;4:546–553.
Al-AhmadieHIyerGHohlM. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov2014;4:1014–1021.
IsakoffSJMayerELHeL. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol2015;33:1902–1909.
CamptonDERamirezABNordbergJJ. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer2015;15:360.
PusztaiLVialeGKellyCMHudisCA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist2010;15:1164–1268.
CriscitielloCAndréFThompsonAM. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res. 2014;16:205.
PritchardCCSalipanteSJKoehlerK. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimensJ Mol Diagn2014;16:56–67.
CraigDWO'ShaughnessyJAKieferJA. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther2013;12:104–116.
GozgitJMWongMJMoranL. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther2012;11:690–699.
ChiariniFEvangelistiCMcCubreyJAMartelliAM. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci2015;36:124–135.
WoolfDKPadhaniARMakrisA. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?Ann Oncol2015;26:1048–1057.
FidlerIJ. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer1973;9:223–227.
LiottaLASaidelMGKleinermanJ. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res1976;36:889–894.
HouJKrebsMGLancashireL. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol2012;30:525–532.
AcetoNBardiaAMiyamotoDT. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell2014;158:1110–1122.
PemovskaTKontroMYadavB. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov2013;3:1416–1429.
TynerJWYangWFBankheadA. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res2013;73:285–296.
OakesSRVaillantFLimE. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA2012;109:2766–2771.
YuMBardiaAAcetoN. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science2014;345:216–220.